Mineralocorticoid Receptors Mediate Diet-Induced Lipid Infiltration of Skeletal Muscle and Insulin Resistance.
Aldosterone
/ metabolism
Animals
CD36 Antigens
/ genetics
Diet, High-Fat
/ adverse effects
Dietary Fats
Dietary Sugars
Fatty Acids, Nonesterified
/ metabolism
Glucose Transport Proteins, Facilitative
/ metabolism
Insulin
/ metabolism
Insulin Resistance
/ physiology
Mice
Mice, Inbred C57BL
MicroRNAs
/ metabolism
Muscle, Skeletal
/ metabolism
Palmitic Acid
/ metabolism
Receptors, Mineralocorticoid
/ metabolism
Spironolactone
/ pharmacology
insulin resistance
microRNA-99a
mineralocorticoid receptor
obesity
skeletal muscle
Journal
Endocrinology
ISSN: 1945-7170
Titre abrégé: Endocrinology
Pays: United States
ID NLM: 0375040
Informations de publication
Date de publication:
11 10 2022
11 10 2022
Historique:
received:
13
05
2022
pubmed:
31
8
2022
medline:
19
10
2022
entrez:
30
8
2022
Statut:
ppublish
Résumé
Excess circulating lipids increase total intramyocellular (IMC) lipid content and ectopic fat storage, resulting in lipotoxicity and insulin resistance in skeletal muscle. Consumption of a diet high in fat and refined sugars-a Western diet (WD)-has been shown to activate mineralocorticoid receptors (MRs) and promote insulin resistance. However, our understanding of the precise mechanisms by which enhanced MR activation promotes skeletal muscle insulin resistance remains unclear. In this study, we investigated the mechanisms by which enhanced MR signaling in soleus muscle promotes ectopic skeletal muscle lipid accumulation and related insulin resistance. Six-week-old C57BL/6J mice were fed either a mouse chow diet or a WD with or without spironolactone (1 mg/kg/day) for 16 weeks. Spironolactone attenuated 16 weeks of WD-induced in vivo glucose intolerance and insulin resistance, and improved soleus insulin metabolic signaling. Improved insulin sensitivity was accompanied by increased glucose transporter 4 (Glut4) expression in conjunction with decreased soleus free fatty acid and IMC lipid content, as well as CD36 expression. Additionally, spironolactone prevented WD-induced soleus mitochondria dysfunction. Furthermore, MR signaling also mediated WD/aldosterone-induced reductions in soleus microRNA (miR)-99a, which was identified to negatively target CD36 and prevented palmitic acid-induced increases in CD36 expression, lipid droplet formation, mitochondria dysfunction, and insulin resistance in C2C12 cells. These data indicate that inhibition of MR activation with spironolactone prevented diet-induced abnormal expression of miR-99a, which had the capacity to reduce CD36, leading to reduced IMC lipid content and improved soleus mitochondria function and insulin sensitivity.
Identifiants
pubmed: 36039677
pii: 6678806
doi: 10.1210/endocr/bqac145
pmc: PMC10233286
pii:
doi:
Substances chimiques
CD36 Antigens
0
Dietary Fats
0
Dietary Sugars
0
Fatty Acids, Nonesterified
0
Glucose Transport Proteins, Facilitative
0
Insulin
0
MicroRNAs
0
Receptors, Mineralocorticoid
0
Spironolactone
27O7W4T232
Palmitic Acid
2V16EO95H1
Aldosterone
4964P6T9RB
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Research Support, U.S. Gov't, Non-P.H.S.
Langues
eng
Sous-ensembles de citation
IM
Subventions
Organisme : NIDDK NIH HHS
ID : R01 DK124329
Pays : United States
Informations de copyright
© The Author(s) 2022. Published by Oxford University Press on behalf of the Endocrine Society. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com.
Références
Horm Metab Res. 2009 Jan;41(1):35-9
pubmed: 18819053
Viruses. 2020 Jun 27;12(7):
pubmed: 32605105
Hypertension. 1995 Jan;25(1):30-6
pubmed: 7843750
Diabetes. 2016 Oct;65(10):2911-9
pubmed: 27411383
Circ Res. 2016 Mar 18;118(6):935-943
pubmed: 26879229
Circulation. 2007 Aug 28;116(9):984-92
pubmed: 17698726
Diabetes. 2019 Jul;68(7):1403-1414
pubmed: 31010957
Am J Physiol Regul Integr Comp Physiol. 2021 Mar 1;320(3):R276-R286
pubmed: 33438511
Am J Physiol Endocrinol Metab. 2008 Jul;295(1):E110-6
pubmed: 18445755
Diabetes. 2017 Jun;66(6):1535-1547
pubmed: 28325853
Adv Drug Deliv Rev. 2022 Feb;181:114110
pubmed: 34995679
Front Endocrinol (Lausanne). 2021 Jun 28;12:694758
pubmed: 34262530
Diabetes. 2013 Feb;62(2):313-9
pubmed: 23349535
RNA. 2006 Jun;12(6):1074-83
pubmed: 16601206
J Clin Endocrinol Metab. 2007 Apr;92(4):1467-73
pubmed: 17244782
Ann Med. 2006;38(6):389-402
pubmed: 17008303
Front Cell Dev Biol. 2020 Dec 03;8:596329
pubmed: 33344451
Circ Res. 2017 Apr 14;120(8):1289-1297
pubmed: 28119423
Mol Cell Endocrinol. 2021 Feb 5;521:111115
pubmed: 33301840
JAMA. 2016 Jun 7;315(21):2284-91
pubmed: 27272580
Cell Biosci. 2011 Sep 21;1(1):31
pubmed: 21936947
Endocrinology. 2011 Jan;152(1):113-25
pubmed: 21084448
Diabetes. 2020 Aug;69(8):1636-1649
pubmed: 32439824
Am J Physiol Cell Physiol. 2012 Feb 15;302(4):C629-41
pubmed: 22031602
Cell Rep. 2020 Jul 14;32(2):107881
pubmed: 32668250
Cells. 2019 Oct 22;8(10):
pubmed: 31652636
Cell Tissue Res. 2016 Dec;366(3):733-746
pubmed: 27503378
Cardiovasc Diabetol. 2013 Nov 21;12:172
pubmed: 24261558
Am J Physiol Heart Circ Physiol. 2015 May 1;308(9):H1126-35
pubmed: 25747754
Diabetes. 2021 Jul;70(7):1486-1497
pubmed: 33863803
J Clin Endocrinol Metab. 2007 Jul;92(7):2552-8
pubmed: 17488800
Diabetes. 2017 Oct;66(10):2583-2595
pubmed: 28768703
Am J Physiol Regul Integr Comp Physiol. 2022 Mar 1;322(3):R253-R262
pubmed: 35107025
FASEB J. 2020 Sep;34(9):11714-11728
pubmed: 32652691
J Clin Invest. 1998 Mar 15;101(6):1254-60
pubmed: 9502766
Menopause. 2020 Sep;27(9):999-1009
pubmed: 32852451
Proc Natl Acad Sci U S A. 2014 Jul 1;111(26):9597-602
pubmed: 24979806
Diabetes. 2019 Jan;68(1):18-20
pubmed: 30573676
Endocrinology. 2010 May;151(5):2040-9
pubmed: 20211973
Cell Death Dis. 2021 Nov 16;12(12):1089
pubmed: 34789726
Biochimie. 2021 Aug;187:83-93
pubmed: 34082043
Hypertension. 2019 Apr;73(4):849-858
pubmed: 30827147
Metabolism. 2017 Jan;66:14-22
pubmed: 27923445
J Physiol. 2020 Sep;598(18):3803-3806
pubmed: 32643165